Holen Sie sich die Stockscreener-App
33.19
9.02%
-3.29
Handel nachbörslich:
33.18
-0.010
-0.03%
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 6.6% Following Insider Selling - MarketBeat
Aug Weekly: Can Stoke Therapeutics Inc grow without external fundingMarket Growth Review & Stock Market Timing Techniques - baoquankhu1.vn
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 33,243 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $174,200.00 in Stock - MarketBeat
Insider Sell: Adrian Krainer Sells 33,243 Shares of Stoke Therap - GuruFocus
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Highs Report: Is Stoke Therapeutics Inc in a long term uptrendPortfolio Risk Report & Reliable Intraday Trade Alerts - baoquankhu1.vn
Cresset Asset Management LLC Invests $771,000 in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD By Investing.com - Investing.com Canada
Stoke Therapeutics (NASDAQ:STOK) Hits New 52-Week HighStill a Buy? - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD - Investing.com South Africa
Stoke Therapeutics earnings in focus amid Dravet trial progress - Investing.com South Africa
Stoke Therapeutics (NASDAQ:STOK) Shares Up 6%Still a Buy? - MarketBeat
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
A Look At Stoke Therapeutics (STOK) Valuation After NEJM Zorevunersen Dravet Syndrome Data Publication - simplywall.st
Stoke Therapeutics Hits New 52-Week High of $39.81, Up 146.41% - Markets Mojo
Stoke Therapeutics Hits Day Low at $33.50 Amid Price Pressure - Markets Mojo
Rhenman & Partners Asset Management AB Invests $5.88 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat
Biogen’s Dravet And SMA Advances Add Depth To Long Term Story - Sahm
Can Stoke Therapeutics Inc. stock deliver sustainable ROE2026 WrapUp & Smart Allocation Stock Reports - Naître et grandir
Vanguard Group Inc. Buys 217,616 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rate Cut: What are the analyst revisions for MESAIs Stoke Therapeutics Inc stock a good investment in YEARWeekly Stock Report & Stepwise Swing Trade Plans - baoquankhu1.vn
How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline - Yahoo Finance
Insider Sell: Adrian Krainer Sells 7,229 Shares of Stoke Therape - GuruFocus
Biogen (BIIB) Reports Promising Data on Zorevunersen for Dravet Syndrome - GuruFocus
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - The AI Journal
Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study - Quiver Quantitative
Stoke Therapeutics (STOK) director sells 7,229 shares under 10b5-1 plan - Stock Titan
Is Stoke Therapeutics (STOK) Still Attractive After A 346% One Year Share Price Surge - simplywall.st
Stoke Therapeutics grants $697,125 bonus to CEO Ian F. Smith By Investing.com - Investing.com Australia
Stoke Therapeutics grants $697,125 bonus to CEO Ian F. Smith - Investing.com South Africa
Stoke Therapeutics Awards Discretionary Bonus to CEO Smith - TipRanks
Stoke Therapeutics (NASDAQ: STOK) awards CEO Ian F. Smith $697,125 2025 bonus equivalent - Stock Titan
STOK: Phase 3 Dravet study nears full enrollment, with strong efficacy and broad market potential - TradingView
Stoke Therapeutics stock hits 52-week high at 38.8 USD By Investing.com - Investing.com Nigeria
STOK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[144] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Sets New 1-Year HighWhat's Next? - MarketBeat
Stoke Therapeutics stock hits 52-week high at 38.8 USD - Investing.com India
Portfolio Shifts: What dividend growth rate does Stoke Therapeutics Inc offerJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
(STOK) Movement as an Input in Quant Signal Sets - Stock Traders Daily
STOK PE Ratio & Valuation, Is STOK Overvalued - Intellectia AI
Stoke Therapeutics (STOK) Investor Outlook: A Promising Biotech with 17.3% Upside Potential - DirectorsTalk Interviews
Stoke Therapeutics Opens with 6.45% Gain, Outperforming S&P 500's 0.69% - Markets Mojo
Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Risk Analysis: What is the earnings history of Stoke Therapeutics IncJuly 2025 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PharmiWeb.com
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK) - TechStock²
Wolfe Research Initiates Coverage on Stoke Therapeutics (STOK) w - GuruFocus
Wolfe Research Initiates Coverage of Stoke Therapeutics (STOK) with Outperform Recommendation - Nasdaq
Forecasting The Future: 5 Analyst Projections For Stoke Therapeutics - Benzinga
A Look At Stoke Therapeutics (STOK) Valuation After Recent Share Price Momentum - Yahoo Finance
Stoke Therapeutics Shares Poised for Pivotal Clinical Updates - AD HOC NEWS
Is Stoke Therapeutics Inc. stock a good pick for beginnersJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):